Epipodophyllotoxin-related leukemia. Identification of a new subset of secondary leukemia

Whitlock, James A.; Greer, John P.; Lukens, John N.

doi:10.1002/1097-0142(19910801)68:3<600::aid-cncr2820680326>3.0.co;2-f

Cited by 158 publications

(42 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients 1 to 10 also received chemotherapy either as adjuvant treatment (patients 1-7, 9 and 10) or as first-line treatment for local and/or distant recurrence (patients 8 and 9). In nine of the patients who received chemotherapy, mitoxantrone was included as first-line treatment in eight cases (patients [1][2][3][4][5][6][7][8] and as treatment of a metastatic recurrence in one case (patient 9). The median latency between the onset of mitoxantrone use and the secondary leukemia was 15 months (range, 11-40).…”

Section: Resultsmentioning

confidence: 99%

“…Futhermore they exhibited characteristics close to those of leukemia related to topoisomerase-II inhibitors: a short latency period, an acute onset rather than an initial myelodysplastic presentation, 7,15 equilibrated translocation in six cases, of which five were specific of FAB subtype: t(15;17)(q22;q21) in M3 sub-type and inv(16)(p13;q22) in M4Eo. 16,17 The initial translocation described in topoisomerase-II inhibitor-related leukemia concerned chromosome 11q23 involving the mixed lineage leukemia gene (MML), 1 which was present in two cases.…”

Section: Discussionmentioning

confidence: 99%

“…Therapy-related leukemia associated with radiotherapy and/or chemotherapy, particularly alkylating agents and topoisomerase II inhibitors, are being reported with increasing frequency. [1][2][3] The most frequently occurring types of therapy-related leukemia are acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). 4 Their incidence varies greatly among studies because of the therapeutic schedule, the number of cases and the primary cancer under treatment.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Increase therapy-related leukemia secondary to breast cancer

Carli¹,

Sgro²,

Parchin-Geneste³

et al. 2000

Leukemia

View full text Add to dashboard Cite

Therapy-related leukemia associated with chemotherapy, particularly alkylating agents and topoisomerase II inhibitors, are being reported with increasing frequency in the literature mainly after breast cancer. We also observed an increasing number of such leukemias in the data base of the specialized registry of hematological malignancies of the Cô te d'Or department. Between 1980 and 1998, 156 AML and RAEB-t were registered in women in Cô te d'Or. Among them, 12 occurred in women with breast cancer history (7.7%). Analysis by period of time shows a significant increase in the proportion of therapyrelated leukemia secondary to breast cancer (P Ͻ 0.02). Chemotherapy including topoisomerase II inhibitors was used in 10 cases in which mitoxantrone was used in eight cases. In these eight cases, leukemia had clinical and biological characteristics usually described with topoisomerase II inhibitors but 44% were promyelocytic sub-type with the t(15;17) specific karyotypic abnormality. These data on a well-defined population demonstrate the increased proportion of therapy-related leukemia secondary to breast cancer, probably due to the use of mitoxantrone. Leukemia

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Increase therapy-related leukemia secondary to breast cancer

Carli¹,

Sgro²,

Parchin-Geneste³

et al. 2000

Leukemia

View full text Add to dashboard Cite

show abstract

“…In 1991, compared with chemotherapy including alkylating agents, etoposideassociated secondary leukemia was characterized by the following: a shorter latency period, the absence of prolonged myelodysplasia, an M4 or M5 phenotype, and abnormalities of chromosome band 11q23. 1,2 Among the patients with etoposide-related AML, Pedersen-Bjergaard et al [3][4][5][6][7] revealed a high frequency of translocations involving chromosome band 11q23 and 21q22. More recently, t-AML with other balanced translocations such as t (15;17), t(8;21), inv (16), t (8;16), and t(9;22) was also reviewed.…”

Section: Etoposide-related Acute Promyelocytic Leukemiamentioning

confidence: 99%

Etoposide-related acute promyelocytic leukemia

et al. 1998

View full text Add to dashboard Cite

The development of therapy-related acute myeloid leukemia (t-AML) has become a growing concern over the past decade, because of the increase in the percentage of long-term survivors of primary malignancy. We reviewed 17 cases with etoposide-related acute promyelocytic leukemia (APL) reported in the literature. The close association between treatment with etoposide for Langerhans cell histiocytosis (LCH) and the development of etoposide-related APL was demonstrated among Japanese and Italians. Our data on the breakpoints (b/ps) of the PML and RAR␣ genes are presented. It is suggested that chromatin structure might be more important than specific consensus sequence in the distribution of b/ps in etoposide-related APL. Keywords: acute promyelocytic leukemia; therapy-related leukemia; etoposide; PML-RAR␣; Langerhans cell histiocytosis Etoposide-related acute promyelocytic leukemiaThe development of therapy-related acute myeloid leukemia (t-AML) has become a growing concern over the past decade, because of the increase in the percentage of long-term survivors of primary malignancy.From the beginning, alkylating agents and radiation have been suspected as the cause of t-AML. In 1991, compared with chemotherapy including alkylating agents, etoposideassociated secondary leukemia was characterized by the following: a shorter latency period, the absence of prolonged myelodysplasia, an M4 or M5 phenotype, and abnormalities of chromosome band 11q23. 1,2 Among the patients with etoposide-related AML, Pedersen-Bjergaard et al 3-7 revealed a high frequency of translocations involving chromosome band 11q23 and 21q22. More recently, t-AML with other balanced translocations such as t(15;17), t(8;21), inv(16), t(8;16), and t(9;22) was also reviewed. 8,9 Since the initial case reports in the 1980s of t-AML following treatment with etoposide, more than 150 such instances have been reported. Topoisomerase-II inhibitors and therapy-related acute myeloid leukemiaEtoposide, inhibitor of the intranuclear enzyme topoisomerase-II (Topo-II), has been used widely as an anticancer drug. Topo-II is able to pass one DNA duplex through another by introducing double-strand breaks in a DNA segment. Normally, the DNA strand breaks produced by Topo-II are quickly resealed. However, in the presence of Topo-II inhibitors the strand breaks persist and the enzyme/DNA complex remains Correspondence: T Naoe, Department of Infectious Diseases, Nagoya University Hospital, 65, Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan; Fax: 81 52 744 2801 Received 24 October 1997; accepted 9 April 1998 stable.10 It was proposed that nonhomologous recombination, which was mediated by Topo-II, resulted in chromosomal translocations involving cellular oncogene. 11The DNA cleavage sites by Topo-II were studied in vitro using naked DNA, and a consensus sequence has been proposed.12,13 However, when the cleavage sites were studied in cultured CCRF-CEM cells exposed to etoposide, they seemed to be associated with the V(D)J recombinase recognition sequences of intron 1 and 3 of...

show abstract

“…[7][8][9] The translocations 11q23, 21q22, or 3q26 and FrenchAmerican-British (FAB) types M4 or M5 are common. [10][11][12][13][14][15][16] Treatment regimens that include alkylators and topoisomerase II inhibitors can increase the risk relative to those agents given individually. 6,17 It has been estimated that tMDS/tAML affects at least 1% of childhood cancer patients, with a higher incidence in children treated for Hodgkin disease (4%).…”

Section: Introductionmentioning

confidence: 99%

Acute myeloid leukemia and myelodysplastic syndrome in children treated for cancer: comparison with primary presentation

Barnard

Lange

Alonzo

et al. 2002

Blood

View full text Add to dashboard Cite

There has not been a reported series of children with therapy-induced myelodysplastic syndrome/acute myeloid leukemia (tMDS/tAML) who were treated systematically. This paper describes 24 children with tMDS/tAML who were assigned randomly to standard-or intensive-timing induction on protocol CCG 2891. Presenting features and outcomes of those children were compared with those of 960 patients with de novo MDS (62 patients) or AML (898 patients). Children with tMDS/ tAML were older at presentation (P ‫؍‬ .015), had lower white blood cell counts (P ‫؍‬ .01), and were more likely to have MDS (21% vs 7%) (P ‫؍‬ .02) and trisomy 8 (P ‫؍‬ .06). Fewer had hepatomegaly (P ‫؍‬ .02), splenomegaly (P ‫؍‬ .03), hepatosplenomegaly (P ‫؍‬ .02), or classic AML translocations [t(8;21), t(15;17), 16q22; P ‫؍‬ .02]. They had a poorer induction rate (50% vs 72%, P ‫؍‬ .016), overall survival (26% vs 47% at 3 years, P ‫؍‬ .007), and event-free survival (21% vs 39% at 3 years, P ‫.)320.؍‬ Disease-free survival after achieving remission was similar (45% vs 53%, P ‫؍‬ .868). Children with tMDS/ tAML who received intensive-timing induction had better outcomes than those who received standard-timing induction (overall survival 32% vs 0%, P ‫؍‬ .54). In this study, the latency period to development of tMDS/tAML was the same for presumed alkylator-induced as for topoisomerase-induced myeloid leukemia. The findings of this study confirm that most children with tMDS/tAML have disease resistant to current therapies. Standardtiming induction appears less effective for this population. (Blood. 2002;100: 427-434)

show abstract

Epipodophyllotoxin-related leukemia. Identification of a new subset of secondary leukemia

Cited by 158 publications

References 44 publications

Increase therapy-related leukemia secondary to breast cancer

Increase therapy-related leukemia secondary to breast cancer

Etoposide-related acute promyelocytic leukemia

Acute myeloid leukemia and myelodysplastic syndrome in children treated for cancer: comparison with primary presentation

Contact Info

Product

Resources

About